“Can confirm the herculean effort of
Dr. Rashidi and CRC Andrea @amfhoeschen in completing the #FMT prophylaxis study at @umnmedschool. 💪
IIT 🚫 industry support.
Valuable study, much learned, excellent effort to move the 🦠💩field forward.
#MSKTOXTCT”
Randomized, double-blinded, placebo-controlled pilot study: Efficacy of faecal microbiota transplantation on chronic fatigue syndrome - Abstract - Europe PMC
Europe PMC is an archive of life sciences journal literature.
“China's first modern and standardized medical center of fecal microbiota transplantation (#FMT) was inaugurated on April 27.
The center is located at the Shanghai New Hongqiao International Medical Zone and will be a world-leading treatment center for clinical intestinal…”
In Silico Analysis of Changes in Predicted Metabolic Capabilities of Intestinal Microbiota after Fecal Microbial Transplantation for Treatment of Recurrent Clostridioides difficile Infection - PubMed
Our findings suggest potential changes in key KO groups post-FMT, which may contribute to FMT efficacy beyond the restored microbial composition/diversity and metabolism of bile acids and short-chain fatty acids. Future larger studies that include a fecal metabolomics analysis combined with animal m …
Gut Microbiota in Anxiety and Depression: Unveiling the Relationships and Management Options - PubMed
The gut microbiota is critical for maintaining human health and the immunological system. Several neuroscientific studies have shown the significance of microbiota in developing brain systems. The gut microbiota and the brain are interconnected in a bidirectional relationship, as research on the mic …
In Silico Analysis of Changes in Predicted Metabolic Capabilities of Intestinal Microbiota after Fecal Microbial Transplantation for Treatment of Recurrent Clostridioides difficile Infection - PubMed
Our findings suggest potential changes in key KO groups post-FMT, which may contribute to FMT efficacy beyond the restored microbial composition/diversity and metabolism of bile acids and short-chain fatty acids. Future larger studies that include a fecal metabolomics analysis combined with animal m …
Study finds stool transplants more effective than antibiotics for treating recurring, life-threatening gut infections
A new study, published in the Cochrane Database of Systematic Reviews and led by an Upstate Medical University professor, has found that compared with standard antibiotic treatment, stool transplantation can increase the number of people recovering from Clostridioides difficile (C. diff) infection, a condition that causes potentially life-threatening diarrhea. Within the study, 77% of people who received a stool transplant did not experience reinfection within eight weeks, compared to 40% of those who received antibiotics alone.
Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA - PubMed
FMBL was found to be cost-effective compared to SOC for the prevention of rCDI with more benefits among patients at first recurrence, with an ICER far below the payer ICER threshold of $100,000. Patients treated with FMBL experienced higher total QALYs and reduced healthcare resource utilization, in …
Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US - PubMed
FMBL has a cost-saving budget impact for a US payer, with higher initial drug costs being offset by savings in rCDI-related medical costs. Greater cost saving was found in patients at first recurrence.
The impact of the COVID-19 pandemic on Clostridioides difficile infection and utilization of fecal microbiota transplantation - PubMed
Previous research has demonstrated that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) gains cell entry through the angiotensin-converting enzyme 2 receptor, which is abundantly found throughout the gastrointestinal (GI) tract, resulting in a wide array of GI manifestations of coro …
Fecal microbiota transplantation for recurrent C. difficile infection in patients with inflammatory bowel disease: A systematic review and meta-analysis - PubMed
Fecal microbiota transplantation (FMT) is known to be highly effective in patients with recurrent Clostridioides difficile infection (rCDI), but its role in patients who also suffer from inflammatory bowel disease (IBD) is unclear. Therefore, we performed a systematic review and meta-analysis to eva …
“#Vowst capsules can be kept at room temp & taken by a patient at home. Dose is 4 capsules once a day for 3 consecutive days. In Phase 3 testing, Vowst showed a #Cdiff recurrence rate of 12.8% compared to a 39.8% rate in placebo group. Results in @NEJM: https://t.co/hMxJswSsJW”
Europe Human Microbiome Market Size, Share, Industry, Forecast to 2029
The Europe Human Microbiome Market 2023 Report makes available the current and forthcoming technical and financial details of the industry It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies It ...
Fecal transplants for babies born by cesarian section may contain harmful pathogens
More than 40% of healthy mothers recruited for a study testing fecal transplantation for babies born by cesarean section tested positive for potentially harmful pathogens, Finnish researchers reported.
Fecal Transplant Benefits C diff Patients Coinfected With COVID-19
Treating Clostridioides difficile infection is complicated in patients coinfected with COVID-19. However, a new study suggests a significant benefit of fecal microbiota transplant (FMT) in these coinfected patients.
Expert reaction to two Cochrane reviews looking at stool transplants for recurrent Clostridium difficile infection, and for inflammatory bowel disease | Science Media Centre
FDA Approves Vowst, the First Oral Live Microbiota Treatment for rCDI
The treatment is the second live microbiota therapeutic approved by the FDA, coming just a few months after the agency approved RBX2660 for recurrent C. difficile infections.
FDA approves pill to treat deadly C. difficile infections
The first-of-its-kind fecal microbiota pill treats recurrent infections caused by Clostridium difficile, an antibiotic-resistant bacterium that's a danger to nursing home residents.
Capsulized Fecal Microbiota Transplantation Induces Remission in Patients with Ulcerative Colitis by Gut Microbial Colonization and Metabolite Regulation - PubMed
Fecal microbiota transplantation (FMT) can induce clinical remission in ulcerative colitis (UC) patients. Enemas, nasoduodenal tubes, and colonoscopies are the most common routes for FMT administration. However, there is a lack of definitive evidence regarding the effectiveness of capsulized FMT tre …
FDA lifts 18-month clinical hold on MaaT Pharma’s microbiome therapeutic
More than a year after imposing a clinical hold on MaaT Pharma’s lead microbiome therapeutic in 2021, the US Food and Drug Administration (FDA) has given clearance for the French firm to begin a phase 3 trial in the US.
Restoring Balance with Advanced Fecal Microbiota Transplantation in C. difficile Infections
Dr Paul Feuerstadt joins Dr David Hudesmand and Dr Jordan Axelrad in a discussion about treatment approaches for C difficile infections, and the latest advances in treating recurrent infections with fecal microbiota transplantation.
FDA approves Seres microbiome drug, as field advances
The FDA approved a new drug from Seres Therapeutics that uses bacteria to treat a bowel disorder, making it the second microbiome therapy to hit the market.
